Radiology. 1990 Nov;177(2):449-53. doi: 10.1148/radiology.177.2.2217783.

Primary Ewing sarcoma: follow-up with Ga-67 scintigraphy.

Radiology

D N Estes, H L Magill, E I Thompson, F A Hayes

PMID: 2217783 DOI: 10.1148/radiology.177.2.2217783

Abstract

While avid accumulation of gallium-67 citrate and technetium-99m methylene diphosphonate (MDP) occurs initially in most cases of primary Ewing sarcoma, uptake after therapy is less well defined. Thirty patients with Ewing sarcoma who underwent Ga-67 and bone scintigraphy at diagnosis, at completion of therapy, and at relapse from 1978 to 1988 were evaluated. All 30 patients showed less primary site Ga-67 activity following therapy. Twenty-three of 28 patients who underwent corresponding bone scintigraphy showed less uptake, but residual activity was usually more intense than with Ga-67. Avid reaccumulation of Ga-67 occurred in four of five patients with primary site relapse, while patients who underwent bone scintigraphy showed less change. It was concluded that a greater decrease in Ga-67 than in Tc-99m MDP uptake often occurs in patients successfully treated for primary Ewing sarcoma. Information obtained at Ga-67 scintigraphy is most likely to be helpful if results of bone scintigraphy remain abnormal or if occult relapse is suspected.

Similar articles

Cited by

Substances

• Gallium Radioisotopes

MeSH terms

• Adolescent
• Adult
• Bone Neoplasms / diagnostic imaging
• Bone Neoplasms / therapy
• Child
• Child, Preschool
• Female
• Follow-Up Studies
• Gallium Radioisotopes*
• Humans
• Male
• Radionuclide Imaging
• Sarcoma, Ewing / diagnostic imaging
• Sarcoma, Ewing / therapy

Publication Types

• Comparative Study
• Journal Article
• Research Support, Non-U.S. Gov't
• Research Support, U.S. Gov't, P.H.S.

Grant support

• CA-21765/CA/NCI NIH HHS/United States
• CA-23099/CA/NCI NIH HHS/United States

LinkOut - more resources

• Full Text Sources
  • Atypon
• Medical
  • Genetic Alliance
  • MedlinePlus Health Information